This study is testing new treatments for people with non-Hodgkin lymphoma that has come back or not responded to previous treatments (relapsed/refractory). Researchers are looking at the safety of a cell therapy called CD19 t-haNK, both alone and in combination with other drugs: N803 (an IL-15 superagonist) and rituximab. You may be eligible if you are at least 18 years old and have CD19- and CD20-positive B-cell non-Hodgkin lymphoma that is active after at least two lines of chemotherapy. The main goal is to see how safe these treatments are, measured within 30 days after each cell infusion. The study aims to enroll up to 20 participants.

Study design

This is an open-label, Phase 1 study, meaning both you and your doctors will know which treatments you are receiving. Up to 20 participants will be randomly assigned to one of two treatment groups.

What's involved

Participants will first receive chemotherapy, followed by a cycle of CD19 t-haNK. After a rest period, you will receive more chemotherapy, then CD19 t-haNK combined with rituximab, or rituximab and N803. This will be followed by up to four additional cycles of the combination treatment without chemotherapy.

Compensation

Not stated in the trial record.

Follow-up

The primary safety outcomes will be measured within 30 days after each cell infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.